 LEXINGTON, Mass., May 20, 2021 GLOBE NEWSWIRE -- Agenus NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the differentiated activity profile of balstilimab, an anti-PD-1 antibody, and new Phase 1 clinical data for AGEN2373, a CD137 agonist antibody, as published in abstracts for two posters to be presented at the American Society for Clinical Oncology ASCO Annual Meeting 2021 from June 4 8, 2021. 